TY - JOUR
T1 - Noninvasive Risk Stratification for Nonalcoholic Fatty Liver Disease Among Living Liver Donor Candidates
T2 - A Proposed Algorithm
AU - Danis, Nilay
AU - Weeks, Sharon R.
AU - Kim, Ahyoung
AU - Baghdadi, Azarakhsh
AU - Ghadimi, Maryam
AU - Kamel, Ihab R.
AU - Saberi, Behnam
AU - Woreta, Tinsay
AU - Garonzik-Wang, Jacqueline
AU - Philosophe, Benjamin
AU - Gurakar, Ahmet
AU - Loomba, Rohit
N1 - Publisher Copyright:
© 2021 by the American Association for the Study of Liver Diseases.
PY - 2022/4
Y1 - 2022/4
N2 - To reduce waitlist mortality, living donor liver transplantation (LDLT) has increased over the past decade in the United States, but not at a rate sufficient to completely mitigate organ shortage. As a result, there are ongoing efforts to expand the living liver donor pool. Simultaneously, the prevalence of nonalcoholic fatty liver disease (NAFLD) in the general population has increased, which has significant implications on the pool of potential living liver donors. As such, a clinical assessment algorithm that exhaustively evaluates for NAFLD and fibrosis is critical to the safe expansion of LDLT. An ideal algorithm would employ safe and noninvasive methods, relying on liver biopsy only when necessary. While exclusion of NAFLD and fibrosis by noninvasive means is widely studied within the general population, there are no well-accepted guidelines for evaluation of living donors using these modalities. Here we review the current literature regarding noninvasive NALFD and fibrosis evaluation and propose a potential algorithm to apply these modalities for the selection of living liver donors.
AB - To reduce waitlist mortality, living donor liver transplantation (LDLT) has increased over the past decade in the United States, but not at a rate sufficient to completely mitigate organ shortage. As a result, there are ongoing efforts to expand the living liver donor pool. Simultaneously, the prevalence of nonalcoholic fatty liver disease (NAFLD) in the general population has increased, which has significant implications on the pool of potential living liver donors. As such, a clinical assessment algorithm that exhaustively evaluates for NAFLD and fibrosis is critical to the safe expansion of LDLT. An ideal algorithm would employ safe and noninvasive methods, relying on liver biopsy only when necessary. While exclusion of NAFLD and fibrosis by noninvasive means is widely studied within the general population, there are no well-accepted guidelines for evaluation of living donors using these modalities. Here we review the current literature regarding noninvasive NALFD and fibrosis evaluation and propose a potential algorithm to apply these modalities for the selection of living liver donors.
UR - http://www.scopus.com/inward/record.url?scp=85121026339&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85121026339&partnerID=8YFLogxK
U2 - 10.1002/lt.26365
DO - 10.1002/lt.26365
M3 - Article
C2 - 34753223
AN - SCOPUS:85121026339
SN - 1527-6465
VL - 28
SP - 670
EP - 677
JO - Liver Transplantation
JF - Liver Transplantation
IS - 4
ER -